Phathom Pharmaceuticals, Inc. (PHAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals
- Person
- Robert Breedlove
- Title
- Vice President, Finance and principal accounting officer
- Action
- resigned
- Effective
- December 4, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
Minimal impact on valuation; investors may monitor subsequent appointments.
Market read
Limited relevance for traders; primarily of interest to current shareholders.
What to watch
Potential hidden restructuring or cost‑cutting plans not disclosed in the filing.
Background
The filing is a standard SEC Form 8‑K announcing an executive departure, typical for public companies.
Ticker impact
SEC 8‑K reports Vice President of Finance Robert Breedlove resigns effective Dec 4 2026.
likely slight downside as market prices in the leadership change
Officer resignation is a routine corporate action for a micro‑cap; no strategic shift disclosed.
Market effects
none
none
none
Counterpoint
The resignation may be a catalyst for a short‑term rally if investors view it as an opportunity for new leadership.
Key entities
- OfficerRobert Breedlove
Vice President, Finance and principal accounting officer resigning



